Vancouver - Inex Pharmaceuticals Corp. announced results from clinical studies indicating its lead anticancer drug, Marqibo, has shown antitumor activity in patients with relapsed non-Hodgkin's lymphoma (NHL), Hodgkin's disease and pediatric malignancies.
"The data presented from these clinical studies continue to demonstrate the activity of Marqibo in a variety of different cancers. Our current focus for Marqibo is finalizing the design of phase III clinical trials in non-Hodgkin's lymphoma and acute lymphoblastic leukemia in order to file Special Protocol Assessments with the FDA as well as continue our discussions with potential development and commercialization partners," David Main, President and CEO of Inex said.
Belleville - Bioniche Life Sciences Inc. has received a US patent on its core mycobacterial cell wall technology, which comprises compositions with antiviral, immune adjuvant, immune stimulatory, and anti-inflammatory activity, as well as chemotherapeutic activity against cancer cells.
Toronto - Tm Bioscience Corp. has signed an agreement to supply Quest Diagnostics (NYSL:DGX) with its Tag-It reagents for use in tests that identify disease-causing genetic mutations. Terms of the agreement were not disclosed. The first products covered under the agreement are Tm Bioscience's ASRs(x) for the GBA, FANCC, IKBKAP, SMPD1, Hex A, BLM, ASPA, and MCOLN1 genes. Mutations in these genes occur at a higher frequency in the Ashkenazi Jewish population.
Vancouver - Cardiome Pharma Corp. and Draxis Health Inc. have been selected to become a members of the Nasdaq Biotechnology Index.
Комментариев нет:
Отправить комментарий